{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:46:40Z","timestamp":1761130000728,"version":"build-2065373602"},"reference-count":55,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH-NCI","award":["SC2CA211029","GM136630-01"],"award-info":[{"award-number":["SC2CA211029","GM136630-01"]}]},{"name":"SC1","award":["SC2CA211029","GM136630-01"],"award-info":[{"award-number":["SC2CA211029","GM136630-01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>We report a retrospective case series of six Hispanic children with tumors treated with metronomic chemotherapy. The six cases comprised one rhabdoid tumor of the kidney, one ependymoma, two medulloblastomas, one neuroblastoma, and a type II neurocytoma of the spine. Treatment included oral cyclophosphamide daily for 21 days alternating with oral etoposide daily for 21 days in a backbone of daily valproic acid and celecoxib. In one case, celecoxib was substituted with sulindac. Of the six patients, three showed complete responses, and all patients showed some response to metronomic therapy with only minor hematologic toxicity. One patient had hemorrhagic gastritis likely associated with NSAIDs while off prophylactic antacids. These data add to a growing body of evidence suggesting that continuous doses of valproic acid and celecoxib coupled with alternating metronomic chemotherapy of agents such as etoposide and cyclophosphamide can produce responses in pediatric tumors relapsing to conventional dose chemotherapy.<\/jats:p>","DOI":"10.3390\/jcm11102849","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T11:59:37Z","timestamp":1652875177000},"page":"2849","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Cyclic Metronomic Chemotherapy for Pediatric Tumors: Six Case Reports and a Review of the Literature"],"prefix":"10.3390","volume":"11","author":[{"given":"Benjamin","family":"Carcamo","sequence":"first","affiliation":[{"name":"Department of Pediatric Hematology Oncology, El Paso Children\u2019s Hospital, El Paso, TX 79905, USA"},{"name":"Department of Pediatrics, Texas Tech University Health Science Center, El Paso, TX 79430, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3752-3070","authenticated-orcid":false,"given":"Giulio","family":"Francia","sequence":"additional","affiliation":[{"name":"Border Biomedical Research Center, University of Texas at El Paso (UTEP), El Paso, TX 79968, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1002\/cncr.28953","article-title":"Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients","volume":"120","author":"Derosa","year":"2014","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrclinonc.2015.89","article-title":"Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trials","volume":"12","author":"Kerbel","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nrclinonc.2016.64","article-title":"Pharmacokinetics of metronomic chemotherapy: A neglected but crucial aspect","volume":"11","author":"Bocci","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrclinonc.2015.131","article-title":"Clinical overview of metronomic chemotherapy in breast cancer","volume":"12","author":"Munzone","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrclinonc.2016.102","article-title":"Paediatrics: Metronomics\u2014Fulfilling unmet needs beyond level A evidence","volume":"13","author":"Andre","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(14)62004-3","article-title":"Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): A phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group","volume":"385","author":"Simkens","year":"2015","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Rochlitz, C., Bigler, M., von Moos, R., Bernhard, J., Matter-Walstra, K., Wicki, A., Zaman, K., Anchisi, S., Kung, M., and Na, K.J. (2016). SAKK 24\/09: Safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer\u2014A multicenter, randomized phase III trial. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2823-y"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/pbc.24794","article-title":"A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer","volume":"61","author":"Robison","year":"2014","journal-title":"Pediatric Blood Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/01.mph.0000183863.10792.d4","article-title":"A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer","volume":"27","author":"Kieran","year":"2005","journal-title":"J. Pediatric Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"23008","DOI":"10.18632\/oncotarget.3984","article-title":"Maintenance chemotherapy in children with ALL exerts metronomic-like thrombospondin-1 associated anti-endothelial effect","volume":"6","author":"Andre","year":"2015","journal-title":"Oncotarget"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"960","DOI":"10.18632\/oncotarget.358","article-title":"Pilot study of a pediatric metronomic 4-drug regimen","volume":"2","author":"Andre","year":"2011","journal-title":"Oncotarget"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/S0149-2918(08)80059-8","article-title":"Metronomic etoposide\/cyclophosphamide\/celecoxib regimen given to children and adolescents with refractory cancer: A preliminary monocentric study","volume":"30","author":"Andre","year":"2008","journal-title":"Clin. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1097\/MPH.0000000000002002","article-title":"Metronomic Maintenance With Weekly Vinblastine After Induction With Bevacizumab-Irinotecan in Children With Low-grade Glioma Prevents Early Relapse","volume":"43","author":"Roux","year":"2021","journal-title":"J. Pediatric Hematol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e28508","DOI":"10.1002\/pbc.28508","article-title":"Metro-SMHOP 01: Metronomics combination with cyclophosphamide-etoposide and valproic acid for refractory and relapsing pediatric malignancies","volume":"67","author":"Benmiloud","year":"2020","journal-title":"Pediatric Blood Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"00950","DOI":"10.3389\/fphar.2018.00950","article-title":"Metronomic Four-Drug Regimen Has Anti-tumor Activity in Pediatric Low-Grade Glioma; The Results of a Phase II Clinical Trial","volume":"9","author":"Verschuur","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3389\/fphar.2017.00792","article-title":"Sustained Complete Response to Metronomic Chemotherapy in a Child with Refractory Atypical Teratoid Rhabdoid Tumor: A Case Report","volume":"8","author":"Berland","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1016\/j.ejca.2010.06.115","article-title":"A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma","volume":"46","author":"Sharp","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"12917","DOI":"10.1073\/pnas.2135406100","article-title":"Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy","volume":"100","author":"Bocci","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1535-7163.MCT-11-0659","article-title":"Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis","volume":"11","author":"Francia","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10456-012-9260-6","article-title":"Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers","volume":"15","author":"Allegrini","year":"2012","journal-title":"Angiogenesis"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/S1470-2045(19)30617-5","article-title":"Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): A multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Bisogno","year":"2019","journal-title":"Lancet. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/pbc.24006","article-title":"Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors","volume":"59","author":"Peyrl","year":"2012","journal-title":"Pediatric Blood Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000336483","article-title":"Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: A multicenter experience","volume":"82","author":"Zapletalova","year":"2012","journal-title":"Oncology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/annonc\/mdf013","article-title":"Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels","volume":"13","author":"Colleoni","year":"2002","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/jnci\/88.24.1840","article-title":"Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide","volume":"88","author":"Chen","year":"1996","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.1996.14.6.1922","article-title":"Response of recurrent medulloblastoma to low-dose oral etoposide","volume":"14","author":"Ashley","year":"1996","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.2174\/138945011795677764","article-title":"Biology of Cox-2: An application in cancer therapeutics","volume":"12","author":"Khan","year":"2011","journal-title":"Curr. Drug Targets"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.seminoncol.2004.03.040","article-title":"Multiple roles of COX-2 in tumor angiogenesis: A target for antiangiogenic therapy","volume":"31","author":"Gately","year":"2004","journal-title":"Semin. Oncol."},{"key":"ref_31","first-page":"150","article-title":"Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs","volume":"39","author":"Kerbel","year":"2007","journal-title":"Cancer Res. Treat. Off. J. Korean Cancer Assoc."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1158\/1078-0432.CCR-05-2849","article-title":"Valproic Acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts","volume":"12","author":"Shu","year":"2006","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccell.2016.02.011","article-title":"HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma","volume":"29","author":"Pei","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0165-4608(90)90215-V","article-title":"Deletion of 5q by t(5;17) in therapy-related myelodysplastic syndrome","volume":"48","author":"Vandenberghe","year":"1990","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.18.01765","article-title":"Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma","volume":"37","author":"Merchant","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e26373","DOI":"10.1002\/pbc.26373","article-title":"A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): A report from the Children\u2019s Oncology Group","volume":"64","author":"Esbenshade","year":"2017","journal-title":"Pediatric Blood Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1200\/JCO.20.02730","article-title":"Children\u2019s Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma","volume":"39","author":"Michalski","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/bmt.2012.276","article-title":"A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children\u2019s Oncology Group study ANBL00P1","volume":"48","author":"Seif","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"iii397","DOI":"10.1093\/neuonc\/noaa222.516","article-title":"MBCL-43. Recurrent Medulloblastoma\u2014Long-term survival with a \u201cMEMMAT\u201d based antiangiogenic approach","volume":"22","author":"Slavc","year":"2020","journal-title":"Neuro-Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"10017","DOI":"10.1200\/jco.2013.31.15_suppl.10017","article-title":"The RIST design: A molecularly targeted multimodal approach for the treatment of patients with relapsed and refractory neuroblastoma","volume":"31","author":"Corbacioglu","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Sun, X., Zhen, Z., Guo, Y., Gao, Y., Wang, J., Zhang, Y., Zhu, J., Lu, S., Sun, F., and Huang, J. (2021). Oral Metronomic Maintenance Therapy Can Improve Survival in High-Risk Neuroblastoma Patients Not Treated with ASCT or Anti-GD2 Antibodies. Cancers, 13.","DOI":"10.3390\/cancers13143494"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e718","DOI":"10.1097\/MPH.0000000000002185","article-title":"Rapid Response to Lorlatinib in a Patient With TFG-ROS1 Fusion Positive Inflammatory Myofibroblastic Tumor of the Chest Wall Metastatic to the Brain and Refractory to First and Second Generation ROS1 Inhibitors","volume":"43","author":"Carcamo","year":"2021","journal-title":"J. Pediatric Hematol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000497380","article-title":"Integration of a Personalized Molecular Targeted Therapy into the Multimodal Treatment of Refractory Childhood Embryonal Tumor with Multilayered Rosettes (ETMR)","volume":"12","author":"Hartman","year":"2019","journal-title":"Case Rep. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/0008-5472.CAN-11-3380","article-title":"VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression","volume":"72","author":"Doloff","year":"2012","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1158\/1535-7163.MCT-08-0200","article-title":"Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-human choriogonadotropin secreting tumor cell lines","volume":"7","author":"Francia","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1593\/neo.10804","article-title":"Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy","volume":"12","author":"Tang","year":"2010","journal-title":"Neoplasia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fonc.2017.00045","article-title":"Therapeutic Targeting of Histone Modifications in Adult and Pediatric High-Grade Glioma","volume":"7","author":"Williams","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_48","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer","volume":"60","author":"Browder","year":"2000","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1126\/science.1127592","article-title":"Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors","volume":"313","author":"Shaked","year":"2006","journal-title":"Science"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1593\/neo.101174","article-title":"Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide","volume":"13","author":"Emmenegger","year":"2011","journal-title":"Neoplasia (New York N.Y.)"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1172\/JCI8829","article-title":"Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity","volume":"105","author":"Klement","year":"2000","journal-title":"J. Clin. Investig."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1200\/jco.2014.32.15_suppl.518","article-title":"SAKK 24\/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer\u2014A multicenter, randomized phase III trial","volume":"32","author":"Rochlitz","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4103\/0019-509X.118741","article-title":"Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a low-income country: Metro-Mali-02","volume":"50","author":"Traore","year":"2013","journal-title":"Indian J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Pramanik, R., Agarwala, S., Sreenivas, V., Dhawan, D., and Bakhshi, S. (2021). Quality of life in paediatric solid tumours: A randomised study of metronomic chemotherapy versus placebo. BMJ Supportive Palliat. Care.","DOI":"10.1136\/bmjspcare-2020-002731"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e28134","DOI":"10.1002\/pbc.28134","article-title":"A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors","volume":"67","author":"Qayed","year":"2020","journal-title":"Pediatric Blood Cancer"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/10\/2849\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:14:13Z","timestamp":1760138053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/10\/2849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":55,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["jcm11102849"],"URL":"https:\/\/doi.org\/10.3390\/jcm11102849","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2022,5,18]]}}}